Absci (ABSI) to Release Earnings on Tuesday

Absci (NASDAQ:ABSI) is expected to announce its earnings results after the market closes on Tuesday, March 18th. Analysts expect the company to announce earnings of ($0.23) per share and revenue of $1.77 million for the quarter. Investors interested in participating in the company’s conference call can do so using this link.

Absci Trading Up 8.3 %

NASDAQ:ABSI opened at $3.14 on Friday. The company has a 50-day moving average price of $3.87 and a 200-day moving average price of $3.70. Absci has a 12 month low of $2.45 and a 12 month high of $6.72. The company has a current ratio of 5.63, a quick ratio of 5.63 and a debt-to-equity ratio of 0.01. The stock has a market cap of $360.65 million, a price-to-earnings ratio of -3.38 and a beta of 2.09.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on ABSI shares. Needham & Company LLC started coverage on shares of Absci in a research report on Wednesday, January 22nd. They issued a “buy” rating and a $9.00 target price for the company. HC Wainwright reissued a “buy” rating and set a $7.00 price target on shares of Absci in a research report on Friday, January 17th. KeyCorp lowered their price target on shares of Absci from $6.00 to $5.00 and set an “overweight” rating for the company in a research report on Wednesday, January 8th. Finally, Guggenheim reissued a “buy” rating and set a $10.00 price target on shares of Absci in a research report on Tuesday, December 3rd. Seven investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Absci has an average rating of “Buy” and an average target price of $8.57.

Absci Company Profile

Absci Corporation operates as a data-first generative artificial intelligence (AI) drug creation company in the United States. The company combines AI with scalable wet lab technologies to create biologics for patients. Its integrated drug creation platform is designed to improve upon traditional biologic drug discovery by using AI to simultaneously optimize multiple drug characteristics that may be important to development and therapeutic benefit.